X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs DISHMAN PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD DISHMAN PHARMA MERCK LTD/
DISHMAN PHARMA
 
P/E (TTM) x 47.9 25.1 190.9% View Chart
P/BV x 7.2 3.3 216.1% View Chart
Dividend Yield % 0.4 0.7 58.9%  

Financials

 MERCK LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
DISHMAN PHARMA
Mar-16
MERCK LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,060374 283.1%   
Low Rs623129 483.3%   
Sales per share (Unadj.) Rs632.4197.8 319.7%  
Earnings per share (Unadj.) Rs45.721.2 215.6%  
Cash flow per share (Unadj.) Rs62.334.7 179.5%  
Dividends per share (Unadj.) Rs11.002.00 550.0%  
Dividend yield (eoy) %1.30.8 164.5%  
Book value per share (Unadj.) Rs388.8179.9 216.1%  
Shares outstanding (eoy) m16.6080.69 20.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 104.6%   
Avg P/E ratio x18.411.9 155.1%  
P/CF ratio (eoy) x13.57.2 186.3%  
Price / Book Value ratio x2.21.4 154.7%  
Dividend payout %24.19.4 255.1%   
Avg Mkt Cap Rs m13,96920,306 68.8%   
No. of employees `0001.60.8 191.0%   
Total wages/salary Rs m1,4875,355 27.8%   
Avg. sales/employee Rs Th6,631.919,252.7 34.4%   
Avg. wages/employee Rs Th939.26,459.5 14.5%   
Avg. net profit/employee Rs Th479.42,064.1 23.2%   
INCOME DATA
Net Sales Rs m10,49815,961 65.8%  
Other income Rs m242265 91.3%   
Total revenues Rs m10,74116,226 66.2%   
Gross profit Rs m1,1354,103 27.7%  
Depreciation Rs m2761,091 25.3%   
Interest Rs m0944 0.0%   
Profit before tax Rs m1,1022,334 47.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m343624 55.1%   
Profit after tax Rs m7591,711 44.4%  
Gross profit margin %10.825.7 42.1%  
Effective tax rate %31.126.7 116.6%   
Net profit margin %7.210.7 67.4%  
BALANCE SHEET DATA
Current assets Rs m6,41011,018 58.2%   
Current liabilities Rs m8,8289,517 92.8%   
Net working cap to sales %-23.09.4 -245.0%  
Current ratio x0.71.2 62.7%  
Inventory Days Days58110 52.2%  
Debtors Days Days3835 110.2%  
Net fixed assets Rs m1,40616,304 8.6%   
Share capital Rs m166161 102.9%   
"Free" reserves Rs m6,28612,907 48.7%   
Net worth Rs m6,45514,516 44.5%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m8,82829,805 29.6%  
Interest coverage xNM3.5-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.5 222.1%   
Return on assets %8.68.9 96.5%  
Return on equity %11.811.8 99.7%  
Return on capital %17.117.5 97.4%  
Exports to sales %8.324.8 33.4%   
Imports to sales %21.03.7 563.2%   
Exports (fob) Rs m8693,956 22.0%   
Imports (cif) Rs m2,209596 370.5%   
Fx inflow Rs m9594,952 19.4%   
Fx outflow Rs m2,612697 374.9%   
Net fx Rs m-1,6534,255 -38.9%   
CASH FLOW
From Operations Rs m1,0702,786 38.4%  
From Investments Rs m-750-1,529 49.0%  
From Financial Activity Rs m-150-941 15.9%  
Net Cashflow Rs m171316 54.0%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 3.7 491.9%  
FIIs % 1.0 12.7 7.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 22.1 131.7%  
Shareholders   28,591 46,261 61.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (4QFY18); Net Profit Up 53.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, MERCK LTD has posted a net profit of Rs 227 m (up 53.2% YoY). Sales on the other hand came in at Rs 3 bn (up 27.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - DIVIS LABORATORIES COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS